1. Home
  2. CRSP vs AVTR Comparison

CRSP vs AVTR Comparison

Compare CRSP & AVTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$53.74

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo Avantor Inc.

AVTR

Avantor Inc.

HOLD

Current Price

$10.18

Market Cap

5.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
AVTR
Founded
2013
1904
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.2B
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
CRSP
AVTR
Price
$53.74
$10.18
Analyst Decision
Buy
Hold
Analyst Count
17
13
Target Price
$70.29
$12.42
AVG Volume (30 Days)
1.6M
9.4M
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
$289,590,000.00
$6,552,200,000.00
Revenue This Year
$807.72
$1.05
Revenue Next Year
$172.52
$1.86
P/E Ratio
N/A
$168.00
Revenue Growth
9169.85
N/A
52 Week Low
$44.12
$7.27
52 Week High
$78.48
$15.93

Technical Indicators

Market Signals
Indicator
CRSP
AVTR
Relative Strength Index (RSI) 53.13 67.09
Support Level $50.17 $7.38
Resistance Level $60.10 $11.35
Average True Range (ATR) 2.57 0.41
MACD 0.19 0.02
Stochastic Oscillator 60.16 82.80

Price Performance

Historical Comparison
CRSP
AVTR

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About AVTR Avantor Inc.

Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.

Share on Social Networks: